Zimmer Biomet (ZBH) announced the Pharmaceutical and Medical Devices Agency, or PMDA, in Japan approved the iTaperloc Complete and iG7 Hip System, the world’s first approved orthopedic implants with Iodine Technology that inhibits bacterial adhesion on the implant surface. Implant-associated bacterial infection or Periprosthetic Joint Infection remains one of the most common causes of revision and a challenging complication of total joint arthroplasty. PJI is estimated to occur in 1-2% of primary TJA procedures and can have serious consequences. Iodine is a biocompatible, essential body nutrient that does not cause antibiotic resistance and is commonly used in medicine as an antiseptic. Iodine Technology applies iodine to the implant’s surface during the manufacturing process to inhibit biofilm formation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet price target raised to $118 from $115 at Stifel
- Target initiated, Nike upgraded: Wall Street’s top analyst calls
- Zimmer Biomet initiated with a Buy at Rothschild & Co Redburn
- Zimmer Biomet Holdings: Operational Improvements and Strategic Positioning Amid Cautious Growth Prospects
- Zimmer Biomet Holdings: Stable Performance with Limited Growth Prospects Justifies Hold Rating